恩格列净治疗常染色体显性多囊肾病的可行性随机对照试验
该先导性可行性随机对照试验纳入50例高进展风险的ADPKD患者,1:1随机接受恩格列净25mg每日一次或安慰剂治疗12个月。主要结局安全性和耐受性两组相似,但恩格列净组肾脏总体积年增长率显著更高(10.5%/年 vs 5.1%/年,P=0.001),eGFR慢性变化率无差异。
要点
- 恩格列净25mg每日一次治疗12个月在ADPKD患者中安全且耐受性良好。
- 恩格列净组身高校正肾脏总体积年增长率显著高于安慰剂组。
- 两组eGFR慢性变化率、血管僵硬度、症状和 copeptin 无差异。
核心结论
- 恩格列净25mg每日一次在ADPKD患者中耐受性良好,但治疗组肾脏体积增长更快。
研究设计与样本
- 先导性可行性随机对照试验,纳入50例18-55岁高进展风险且未接受托伐普坦治疗的ADPKD患者,1:1随机分配至恩格列净25mg每日一次或安慰剂治疗12个月。
主要发现
- 平均年龄42±7岁,eGFR为70±17 ml/min per 1.73 m2。
- 不良事件频率两组相似;恩格列净组2例尿路感染,安慰剂组0例;安慰剂组1例AKI。
- 每组96%的参与者耐受全剂量研究药物。
- 身高校正肾脏总体积年变化率:恩格列净组10.5%/年(95%CI 8.2%-12.7%),安慰剂组5.1%/年(95%CI 3.0%-7.3%),P=0.001。
- 1个月时eGFR急性下降:恩格列净组-6.2 ml/min per 1.73 m2,安慰剂组0.1 ml/min per 1.73 m2,P=0.01;1至12个月eGFR变化无差异(恩格列净组-0.77±1.44 vs 安慰剂组-2.87±1.96 ml/min per 1.73 m2 per year,P=0.4)。
临床怎么用
- 恩格列净25mg每日一次在ADPKD患者中安全可耐受,但需注意肾脏体积可能增长更快。
局限性
- 本研究为先导性可行性试验,样本量小(50例),主要结局为安全性和耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Empagliflozin 25 mg once daily for 12 months was safe and well tolerated in adults with autosomal dominant polycystic kidney disease at high risk of rapid progression. Those randomized to empagliflozin had a greater rate of increase in total kidney volume over 12 months compared with placebo. There was no difference between groups in the chronic rate of change in eGFR, nor in change in vascular stiffness, symptoms, and copeptin. BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of diabetic and nondiabetic kidney disease progression; however, their safety and efficacy in patients with autosomal dominant polycystic kidney disease (ADPKD) are undetermined. METHODS: In this pilot and feasibility randomized controlled trial, we assigned 50 participants, 18-55 years of age, with ADPKD, at high risk of progression, not treated with tolvaptan, to receive empagliflozin (25 mg once daily) or placebo in a 1:1 ratio for 12 months. Primary outcomes were medication safety and tolerability. Secondary outcomes were (1) change in height-adjusted total kidney volume; (2) acute and chronic slope of eGFR; and (3) changes in aortic pulse wave velocity, plasma copeptin levels, urine kidney injury molecule-1, and patient-reported outcomes. RESULTS: Mean age was 42±7 years, and eGFR was 70±17 ml/min per 1.73 m2. Frequency of adverse events was similar between the 2 groups. Urinary tract infection occurred in 2 empagliflozin-treated patients versus none in placebo and AKI in 1 placebo-treated patient. In total, 96% of the participants in each group tolerated the full dose of the study drug. Among the secondary outcomes, rate of change in height-adjusted total kidney volume was significantly greater in empagliflozin-treated participants (10.5%/yr; 95% confidence interval, 8.2% to 12.7%) compared with placebo (5.1%/yr; 95% confidence interval, 3.0% to 7.3%; P = 0.001). There was a faster acute decline in eGFR at 1 month among the empagliflozin (-6.2 ml/min per 1.73 m2) versus placebo groups (0.1 ml/min per 1.73 m2; P = 0.01), but no differences in eGFR change from 1 to 12 months (empagliflozin group: -0.77±1.44 ml/min per 1.73 m2 per year versus placebo group: -2.87±1.96 ml/min per 1.73 m2 per year; P = 0.4). No between-group differences were observed in changes in aortic pulse wave velocity, copeptin, urine kidney injury molecule-1, and ADPKD Impact Score. CONCLUSIONS: Empagliflozin at 25 mg once daily was well tolerated by patients with ADPKD. Empagliflozin induced an expected acute decline in eGFR by 1 month, followed by stable eGFR. However, those treated with empagliflozin had a greater increase in kidney volume. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT05510115.
引用
- Seliger SL, Gitomer B, You Z, et al. Empagliflozin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial. J Am Soc Nephrol. 2026. PMID: 42925875. doi:10.1681/ASN.0000001271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。